X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): respiratory-chain abnormalities in cultured fibroblasts

Barth, P.G.; van den Bogert, C.; Bolhuis, P.A.; Scholte, H.R.; van Gennip, A.H.; Schutgens, R.B.H.; Ketel, A.G.

Published in:
Journal of inherited metabolic disease

DOI:
10.1007/BF01799418

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

UvA-DARE is a service provided by the library of the University of Amsterdam (http://dare.uva.nl)

Download date: 26 Nov 2018
Short Communication

X-Linked cardioskeletal myopathy and neutropenia (Barth syndrome):
Respiratory-chain abnormalities in cultured fibroblasts

P. G. BARTH1,2*, C. VAN DEN BOGERT1,2, P. A. BOLHUIS2, H. R. SCHOLTE3,
A. H. VAN GENNIP1, R. B. H. SCHUTGENS1 and A. G. KETEL4
1Department of Pediatrics, 2Department of Neurology, Emma Children’s Hospital,
Academic Medical Centre, Amsterdam; 3Department of Biochemistry, Erasmus
University, Rotterdam; 4Department of Pediatrics, Spaarneziekenhuis, Haarlem,
The Netherlands

*Correspondence: Division of Pediatric Neurology, Emma Children’s Hospital,
Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

X-Linked cardioskeletal myopathy, neutropenia and abnormal mitochondria (McKusick
302060; 3-methylglutaconic aciduria type 2; Barth syndrome) represents a rare metabolic
disorder with a distinct clinical phenotype, reported so far from Europe (Barth et al 1983),
North-America (Gibson et al 1991; Kelley et al 1991) and Australia (Adès et al 1993;
Christodoulou et al 1994). It has the following clinical and biochemical profile: dilated
cardiomyopathy; neutropenia due to maturation arrest; neuromuscular weakness; absence
of cerebral involvement; and diminished statural growth. Clinical biochemical features
include variable lactic acidaemia and lactic aciduria (Barth et al 1983); increased urinary
excretion of 3-methylglutaconic acid, 3-methylglutaric acid and 2-ethylhydracrylic acid
(Kelley et al 1991; Gibson et al 1991); and low serum cholesterol (Kelley et al 1991).
Linkage analysis assigned the disease to distal Xq28 (Bolhuis et al 1991; Adès et al 1993;
Christodoulou et al 1994). Previous studies on the respiratory chain in skeletal muscle
showed impaired oxidative phosphorylation at the level of complexes III and IV (Barth et
al 1983) and decreased activity of complex IV (Christodoulou et al 1994). Results of
clinical experiments pertaining to the organic acid abnormality and the low serum
cholesterol included absent effect of leucine loading on the excretion of 3-methylglutaconic
acid (Kelley et al 1991; Christodoulou et al 1994); normal activities of enzymes in
the leucine pathway (3-methylglutaconyl-CoA hydratase (EC 4.2.1.18), 3-hydroxy-3-
methylglutaryl-CoA lyase (EC 4.1.3.4), 3-hydroxy-3-methylglutaryl-CoA reductase); and

By ascertaining respiratory-chain function in cultured fibroblasts we expected to
establish whether respiratory-chain abnormalities extend to other tissues beyond striated muscle. Furthermore, we wanted to exclude the possibility that such abnormalities were associated with mutated or depleted mitochondrial DNA (mtDNA) by studying the in vitro biosynthesis of mitochondrially encoded subunits of the relevant complexes.

MATERIALS AND METHODS

Fibroblasts were obtained from two patients from different pedigrees. Patient 1 belonged to an earlier described family (Barth et al. 1983), patient 2 to a recently discovered new family.

Mitochondrial ATP synthesis was measured in fibroblasts from exponentially growing cultures, permeabilized with low concentrations of digitonin (1 μg/10⁶ cells). ATP synthesis was initiated by the addition of ADP to a final concentration of 10 mmol/L. Glutamate (10 mmol/L) + malate (2 mmol/L) or pyruvate (10 mmol/L) + malate (2 mmol/L) were used as substrates for oxidative phosphorylation via complexes I, III and IV. Succinate (10 mmol/L) (+2 μg rotenone/ml to inhibit complex I) was used as a substrate for oxidative phosphorylation via complexes II, III and IV.

Mitochondrial protein synthesis: After removing the normal culture medium, fibroblasts from exponentially growing cultures were rinsed twice with PBS and cultured in methionine-free DME containing 1 mmol/L pyruvate and supplemented with 10% heat-inactivated fetal calf serum in a humidified atmosphere of 10% CO₂ in air. After 1 h [³⁵S]methionine (specific activity >960 Ci/mmol) was added to a final concentration of 20 μCi/ml. Emetine labelling was used to suppress cytoplasmic protein synthesis. Emetine was added 10 min before the addition of labelled methionine, to a final concentration of 100 μg/ml. Equal amounts of labelled cells were solubilized by lauryl maltoside treatment. The samples were centrifuged and the supernatants were subjected to electrophoresis as described (Schägger and Von Jagow 1987). The gels were dried under vacuum and labelled mitochondrial proteins were visualized by fluorography. The autoradiographic signals of the proteins were quantified on gels using a Phospho Imager.

The activity of individual respiratory-chain enzymes was determined in freshly prepared cell lysates, obtained by treatment with lauryl maltoside, according to standard methods (Nijtmans et al. 1995).

PATIENTS

Patient 1: This patient, described previously (Barth et al. 1983) (pedigree no. V, 12), had neonatal lactic acidosis (up to 13.9 mmol/L). On follow-up he had moderate muscle weakness, neutropenia, and dilated cardiomyopathy. He died from cardiac failure at 15 months. Myocardial mitochondria were abnormal in structure.

Patient 2: This patient was not related to patient 1. His maternal uncle died in infancy with a similar history. The proband had failure to thrive (statural length on the 3rd centile, weight below the 3rd centile), dilated cardiomyopathy, and increased excretion of 3-methylglutaconic acid and 3-methylglutaric acid. He died, probably from cardiac failure, at 13 months. Dilated cardiomyopathy was found at autopsy.
Table 1  ATP synthesis

<table>
<thead>
<tr>
<th>Substrate</th>
<th>Patient 1 (n=4)</th>
<th>Patient 2 (n=2)</th>
<th>Control (n=10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glutamate/malate</td>
<td>18.1 (83%)</td>
<td>19.5 (88%)</td>
<td>22.0 (18.4–28.3)</td>
</tr>
<tr>
<td>Pyruvate/malate</td>
<td>15.5 (75%)</td>
<td>17.6 (85%)</td>
<td>20.7 (16.4–26.4)</td>
</tr>
<tr>
<td>Succinate (+rotenone)</td>
<td>11.2 (70%)</td>
<td>14.6 (91%)</td>
<td>15.9 (12.9 –18.6)</td>
</tr>
</tbody>
</table>

*Activity expressed as nmol ATP/mg protein per min; % is percentage of normal mean

Table 2 Mitochondrial enzyme activities

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Patient 1 (n)</th>
<th>Patient 2 (n)</th>
<th>Control mean (range)</th>
<th>(n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complex I</td>
<td>3.0 (4)</td>
<td>3.4 (2)</td>
<td>3.6 (3.0–4.1)</td>
<td>(11)</td>
</tr>
<tr>
<td>Complex II</td>
<td>7.9 (4)</td>
<td>6.7 (2)</td>
<td>7.6 (5.6 –7.8)</td>
<td>(11)</td>
</tr>
<tr>
<td>Complex III</td>
<td>3.2 (4)</td>
<td>3.7 (4)</td>
<td>11.1 (10.2–14.9)</td>
<td>(9)</td>
</tr>
<tr>
<td>Complex IVb</td>
<td>0.31 (10)</td>
<td>0.42 (8)</td>
<td>0.58 (0.45–0.62)</td>
<td>(53)</td>
</tr>
<tr>
<td>Citrate synthase</td>
<td>87 (6)</td>
<td>75 (4)</td>
<td>78 (58–86)</td>
<td>(53)</td>
</tr>
</tbody>
</table>

*Activities expressed as nmol/mg protein per min
bComplex IV: k (per min per mg)

RESULTS

Electrophoresis of polypeptides, labelled in the presence of emetine, showed no abnormalities in the mobility or the incorporation of radioactivity of mitochondrially encoded proteins. This suggests that the expression of mtDNA was normal in the fibroblasts from the patients.

Results of respiratory-chain studies are given in Tables 1 and 2.

CONCLUSIONS

The ATP production from glutamate + malate, pyruvate + malate, or succinate (+rotenone) was lower than the mean values found in control fibroblasts in patient 1 and in the low-normal range in patient 2. Decreased activities of complex III (±30% of controls) and complex IV (±60% of controls) are in agreement with the previous studies in muscle. These findings provide evidence that respiratory-chain dysfunction is an essential component of Barth syndrome. Results further indicate that the gene product is essential for the function, formation or stability of both complex III and complex IV. Both complex III and complex IV contain subunits that are encoded by mtDNA. The results of emetine labelling make it unlikely that the gene is involved in the expression of mtDNA. We furthermore suspect that 3-methylglutaconic aciduria in this syndrome represents an epiphenomenon which is as yet unexplained but has been described so far in patients with separate mitochondrial disorders (Gibson et al 1995).

REFERENCES


